PIN4 A BUDGET IMPACTO ANALYSIS OF TENOFOVIR ALAFENAMIDE/EMTRICITABINE (DESCOVY®) FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PATIENTS AGED 12 YEARS AND OLDER, IN MEXICO

Abstract

The Mexican health system offers universal access to antiretroviral (ARV) drugs. The economic burden, despite off-patent antorretriviral antirretroviral, remains high. Even with a low prevalence, at the end of 2018, 164,074 Mexicans are living with HIV and require ARV treatment. DESCOVY® (TENOFOVIR ALAFENAMIDE/EMTRICITABINE, FTC/TAF) use in combination with other antiretrovirals (ARVs) has the potential to low the current economic burden when compare to Abacavir/lamivudina (ABC/3TC), Emtricitabina/tenofovir disoproxil fumarato (FTC/TDF) and succiante (FTC/TDS), current therapies use in the treatment of patients aged 12 years and older diagnosed with human immunodeficiency virus type 1 (HIV-1) in Mexico. A budget impact model with a 5-year time horizon was developed. The aim of this Budget Impact Analysis is to estimate the difference in current annual expenditures versus a new scenario in wich FTC/TAF is included and increases its share in 30%, 50% and 70% form the starting scenario. Current Mexican market shares of triple regimens containing first-choice or alternative backbones ABC/3TC, FTC/TDF and FTC/TDS, in the new scenario is compared to FTC/TAF. Annual cost for each regimen only comprises drugs acquisition. According to current prescribing trends, in the next 5 years about 423 patients starting HIV therapy will receive ABC/3TC, FTC/TDF. In the new scenario, when 30% share of patients are elegible the savigns generate by FTC/TAF are $583,549 USD (496,987-602,325), when the saher increases to 50% patients that would be eligible to FTC/TAF it leads to a cumulative saving of $833,642 USD ($745,987-$980,776), finally when 70% patients are elegible the savings are $1,083,734.60 USD ($965,786$1,724,998). If backbones ABC/3TC, FTC/TDF and FTC/TDS are displaced, the introduction of FTC/TAF (Descovy®) would be cost saving. At national level would lead to a reduction of direct medical costs over a 5-year period for the Mexican health system without affecting therapeutic efficacy.